Effects of pentosan polysulfate on peripheral blood leukocyte populations and mononuclear cell procoagulant activity in patients with osteoarthritis

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 2, 1997, Pages 93-107

  Anderson, Janet M ^a   Edelman, Jack ^b   Ghosh, Peter ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

leukocytes; mononuclear cell procoagulant activity; osteoarthritis; pentosan polysulfate

Indexed keywords

PENTOSAN POLYSULFATE;

ADULT; AGED; ARTICLE; BLOOD; BLOOD CLOTTING; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; INTRAMUSCULAR DRUG ADMINISTRATION; LEUKOCYTE; LYMPHOCYTE; MONOCYTE; MONONUCLEAR CELL; NEUTROPHIL; OSTEOARTHRITIS; PRIORITY JOURNAL;

EID: 0030899324     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80118-X     Document Type: Article

References (53)

1. Banjeree S, Poole A. Immunity to cartilage proteoglycan. J Rheumatol. 1992;33(Suppl): 36-39.
2. Poole AR. Immunology of cartilage. In: Moskowitz RW, Howell DS, Goldberg VM, Mankin HJ, eds. Osteoarthritis. 2nd ed. Philadelphia: WB Saunders; 1992;155-189.
3. Giant T, Mikecz K, Kuettner KE, Thonar EJ-MA. Immune responses to cartilage proteoglycans in inflammatory animal models and human disease. In: Woessner F, Howell D, eds. Joint Cartilage Degradation: Basic and Clinical Aspects. New York: Marcel Dekker; 1992:435-473.
4. Charriere G, Hartmann DJ, Vignon E, et al. Antibodies of types I, II, DC, and XI collagen in the serum of patients with rheumatic disease. Arthritis Rheum. 1988;31:325-332.
5. Alsalameh S, Mollenhauer J, Hain N, et al. Cellular immune response towards human articular chondrocytes - T cell reactivities against chondrocyte and fibroblast membranes in destructive joint diseases. Arthritis Rheum. 1990;3:1477-1486.
6. Gurr E, Ahrens A, Lonnemann G, Delbruck A. Increased interleukin-1β production of macrophages by proteoglycan fragments derived from articular cartilage (in vitro). Agents Actions. 1990;29:117-119.
7. Anderson J, Bansal M, Danis V, Ghosh P. Stimulation of peripheral blood mononuclear cells by cartilage degradation. J Leukocyte Biol. 1993;5:100. Abstract.
8. Ghosh P, Smith M. The role of cartilage-derived antigens, procoagulant activity and fibrinolysis in the pathogenesis of osteoarthritis. Med Hypotheses. 1993;41:190-194.
9. Lohmander LS. Articular cartilage and osteoarthritis - The role of molecular markers to monitor breakdown, repair and disease. J Anat. 1994;184:477-492.
10. Lohmander LS, Dahlberg L, Ryd L, Heinegård D. Increased levels of proteoglycan fragments in knee joint fluid after injury. Arthritis Rheum. 1989;32:1434-1442.
11. Sharif M, Emmanuel G, Dieppe PA. Correlation between synovial fluid markers of cartilage and bone turnover and scintigraphic scan abnormalities in osteoarthritis of the knee. Arthritis Rheum. 1995;38:78-81.
12. Arnoldi CC, Lempberg RK, Linderholm H. Intraosseous hypertension and pain in the knee. J Bone Jt Surg Ser B. 1975;57B:360-364.
13. Kiaer T. The intraosseous circulation and pathogenesis of osteoarthritis. Med Sci Res. 1987;15:759-763.
14. Cheras PA, Freemont AJ, Skorsky JM. Intraosseous thrombosis in ischemic necrosis of bone and osteoarthritis. Osteoarthritis Cartilage. 1993;1:210-232.
15. Theiler R, Ghosh P, Brooks P. Clinical assessment methods in osteoarthritis and clinical trials with chondromodulating agents. Osteoarthritis Cartilage. 1994;3:1757-1774.
16. Huskisson EC, Berry H, Gishen P, et al. Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. J Rheumatol. 1995;22:1941-1946.
17. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract, the double-edged sword. Arthritis Rheum. 1995;38:5-18.
18. Peyron JG. Intraarticular hyaluronan injections in the treatment of OA. State-of-the-art review. J Rheumatol. 1993;20(Suppl 39):10-15.
19. McIlwain H, Silverfield JC, Cheatum DE, et al. Intra-articular orgotein in osteoarthritis of the knee. A placebo-controlled efficacy, safety and dosage comparison. Am J Med. 1989;87:295-300.
20. Setnikar I. Antireactive properties of chondroprotective drugs. Int J Tissue React. 1992; 14:253-261.
21. Ghosh P, Smith M, Wells C. Second-line agents in osteoarthritis. In: Dixon JS, Furst DE, eds. Second Line Agents in the Treatment of Rheumatic Disease. New York: Marcel Dekker; 1992:363-428.
22. Rogachefsky RA, Dean DD, Howell DS, Altman RD. Treatment of canine osteoarthritis with insulin-like growth factor-1 (IGF-1) and sodium pentosan polysulphate. Osteoarthritis Cartilage. 1993;11:105-114.
23. Collier SA, Ghosh P. Evaluation of the effects of antiarthritic drugs on the secretion of proteoglycans by lapine chondrocytes using a novel assay procedure. Ann Rheum Dis. 1989;48:372-381.
24. Hutadilok N, Smith M, Cullis-Hill D, Ghosh P. Pentosan polysulphate stimulates hyaluronate and DNA synthesis in synovial fibroblasts and partially reduces the suppressive effect of hydrocortisone on fibroblast metabolism. Curr Ther Res. 1988;44:845-860.
25. Francis DJ, Hutadilok N, Kongtawelert P, Ghosh P. Pentosan polysulphate and glycosaminoglycan polysulphate stimulate the synthesis of hyaluronan in vivo. Rheumatol Int. 1993;13:61-64.
26. Bansal MK, Smith MM, Numata Y, Ghosh P. The effects of calcium pentosan polysulfate on inflammatory mediators in the rat air-pouch model of inflammation. Curr Ther Res. 1993;54:714-730.
27. Smith MM, Numata Y, Bowman L, Ghosh P. Calcium pentosan polysulphate given orally to rabbits with inflamed knee joints abrogates interleukin-1-induced antiproliferative effects and reduces nitric oxide but not interleukin-6 activity in ex vivo cultures of synovial fibroblasts. Arthritis Rheum. 1995;38(Suppl):1312. Abstract.
28. Smith MM, Ghosh P, Numata Y, Bansal M. The effect of orally administered calcium pentosan polysulphate on inflammation and cartilage degradation produced in rabbit joint by intraarticular injection of a hyaluronate-polylysine complex. Arthritis Rheum. 1994;37:125-136.
29. ®) in 105 patients with OA of the knee. Osteoarthritis Cartilage. 1994;2(Suppl 1):35. Abstract.
30. Kongtawelert P, Ghosh P. A monoclonal antibody that recognizes 2,3-, 2,6-, and 4,6-disulphated ester ring substitution in pyranose-containing polysaccharides. Its production, characterization and application for the quantitation of pentosan polysulphates, dextran sulphate, glycosaminoglycan polysulphate and chondroitin sulphate E. J Immunol Methods. 1990;126:39-49.
31. Kellgren JK, Lawrence JS. Radiological assessment of osteoarthritis. Ann Rheum Dis. 1957;16:494-501.
32. Kongtawelert P, Francis DJ, Brooks PM, Ghosh P. A new sandwich ELISA method for the determination of keratan sulphate peptides in biological fluids employing a monoclonal antibody and labelled avidin biotin technique. Clin Chim Acta. 1990;195:17-26.
33. Geczy CL, Jones A. Procoagulant induction by human lymphokine and interferon γ/PMA on a myelomonocytic cell line, RC2A. Br J Haematol. 1988;70:211-218.
34. McNeil D. On graphing paired data. Am Statistician. 1992;46:307-311.
35. Geczy CL, Meyer PA. Leukocyte procoagulant activity in man: An in vitro correlate of delayed-type hypersensitivity. J Immunol. 1982;128:331-336.
36. Gregory SA, Edgington TS. Tissue factor induction in human monocytes. J Clin Invest. 1985;76:2440-2445.
37. Edwards RL, Rickles FR. The role of human T cells (and T cell products) for monocyte tissue factor generation. J Immunol. 1980;125:606-609.
38. Rothberger H, Zimmerman TS, Spiegelberg HL, Vaughan JH. Leukocyte procoagulant activity. Enhancement of production in vitro by IgG and antigen-antibody complexes. J Clin Invest. 1977;59:549-557.
39. Witter J, Roughley PJ, Webber C, et al. The immunologic detection and characterization of cartilage proteoglycan degradation in synovial fluids of patients with arthritis. Arthritis Rheum. 1987;30:519-529.
40. Hascall VC, Giant T. Proteoglycan epitopes as potential markers of normal and pathological cartilage metabolism. Arthritis Rheum. 1987;30:586-588.
41. Prydz H, Allison AC. Tissue thromboplastin activity of isolated human monocytes. Thromb Haemost. 1978;39:582-591.
42. Clemmensen I, Hølund B, Anderson RB. Fibrin and fibronectin in rheumatoid synovial membrane and rheumatoid synovial fluid. Arthritis Rheum. 1983;26:479-485.
43. Weinberg JP, Pippen AMM, Greenberg CS. Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 1991;34:996-1005.
44. Zacharski LR, Brown FE, Memoli VA, et al. Pathways of coagulation activation in situ in rheumatoid synovial tissue. Clin Immunol Immunopathol. 1992;63:155-162.
45. Lorand L, Conrad SM. Transglutaminases. Mol Cell Biochem. 1984;58:9-35.
46. Drake TA, Morrissey JH, Edgington TS. Selective expression of tissue factor in human tissues: Implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989;134: 1087-1097.
47. 3H] adenosine-labeled mouse lymph node cells. Cell Immunol. 1977;31:62-76.
48. Hall JG. Sulphated polysaccharides, corticosteroids and lymphocyte recirculation. Immunology. 1986;57:275-279.
49. Spangrude GJ, Braaten BA, Daynes RA. Molecular mechanism of lymphocyte extravasation. I: Studies of two selective inhibitors of lymphocyte recirculation. J Immunol. 1984;132:354-362.
50. Bevilacqua MP, Nelson RM. Endothelial-leukocyte adhesion molecules in inflammation and metastasis. Thromb Haemost. 1993;70:152-154.
51. Sugiyama E, Kuroda A, Taki H, et al. Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatology synovial cells. J Rheumatol. 1995;22:2020-2026.
52. van Roon JA, van Roy JL, Duits A, et al. Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial T helper-1 activation is inhibited by interleukin-4. Ann Rheum Dis. 1995;54:836-840.
53. Yeh L, Augustine AJ, Lee P, et al. Interleukin-4, an inhibitor of cartilage breakdown in bovine articular cartilage. J Rheumatol. 1995;22:1740-1746.